Full-Time

Buyer/Planner

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Mid

Bridgewater Township, NJ, USA

Category
Inventory Management
Procurement & Sourcing
Supply Chain Management
Operations & Logistics
Required Skills
Power BI
Visio
Excel/Numbers/Sheets
Requirements
  • Minimum: Bachelor’s degree in supply chain, Finance, Accounting, Engineering, Business or related field.
  • A minimum of 3 years relevant Supply Chain and Procurement experience is required.
  • Ability to work independently and successfully, prioritize and manage multiple tasks simultaneously, integrate cross-functional issues and balance competing priorities effectively. Must be able to manage shifting priorities to meet critical deadlines in a fast paced and dynamic, growing environment.
  • Strength in communicating and working effectively with broad stakeholders in various scientific/technical/business disciplines.
  • Very strong influencing capabilities with an ability to interact and communicate effectively at all levels of the organization and across different functions.
  • Ability to promote a mindset of continuous improvement, problem solving, and prevention.
  • Technologically savvy with the ability to quickly adopt new systems and processes. Proficient in Excel (Pivot Tables and Advanced Analytics), Word, Power BI, Visio, and exposure to ERP and other financial accounting systems.
Responsibilities
  • Interpret and analyze demand and usage of various materials including (but not limited to) critical supplies, clinical materials, components and consumables.
  • Participate in regular Site Supply Chain / Planning meetings (e.g. S&OP and LRP) to evaluate manufacturing plans to ensure inventory coverage and supply readiness.
  • Monitor supplier execution and deliverables of goods and services aligned with scope of work.
  • Monitor product life cycles and alert appropriate team members to any actionable inventory requirements and disruption to supply.
  • Maintain system planning parameters (e.g. lot size, lead-time and safety stock levels) within the site ERP.
  • Assist with the development of investigations and root cause analyses on any supply disruptions or material quality related issues.
  • Support Quality, Regulatory and Financial audits.
  • Provide timely responses to business units’ representative(s) and suppliers' inquiries.
  • Assist with the development and implementation of standard operating procedures, work instructions and training materials.
  • Support end to end supply chain activities and work collaboratively with the wider supply chain team to support base business activities.
  • Support creation and maintenance of supply chain procedures, work instructions, forms and applicable documentation to comply with GMP regulations.
Desired Qualifications
  • Experience in Pharma or Biologics manufacturing / Supply Chain is highly preferred.
  • SAP – Advanced Supply Chain Planning is highly preferred.

Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers affecting the blood and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company focuses on personalized medicine, which tailors therapies to individual patients. They not only discover and develop new therapies but also bring them to market, generating revenue through licensing and sales. A notable product is their CAR-T therapy, which modifies a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial performance and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $150M investment in Belgium facility shows commitment to expanding production capabilities.
  • Alan Bash's appointment strengthens leadership in CAR-T therapy market.
  • New R&D facility in Philadelphia focuses on next-generation cell therapies.

What critics are saying

  • Increased competition from Amgen's Imdelltra could impact market share.
  • Collaboration with Multiply Labs may face challenges in scaling up production.
  • Expansion of R&D facilities requires significant investment, potentially straining resources.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Fierce Pharma
Mar 12th, 2025
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms.

The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.